Gemcitabine Resistance Requires the Sustained Uptake of Calcium via L-Type Channels and is Reversed by High Dose Amlodipine

Presenter: Daniel Principe
Mentor: Ajay Rana, PhD

Gemcitabine Resistance Requires the Sustained Uptake of Calcium via L-Type Channels and is Reversed by High Dose Amlodipine

Gemcitabine is among the most widely used medications in the treatment of pancreatic cancer. While Gemcitabine-based chemotherapy modestly prolongs survival in both localized and disseminated disease, nearly all tumors either have or will develop some degree of drug resistance. With no approved medications for patients who progress on chemotherapy, the aim of this study was to identify the cellular mechanisms that allow tumor cells to resist Gemcitabine in hopes of exploiting them for therapy.

Using single cell RNA sequencing and whole proteome analysis, Principe and his colleagues found that Gemcitabine resistance is dependent on the ability of tumor cells to take up large amounts of extracellular calcium. The cells then use this influx of calcium to activate the protein Calmodulin to enhance pro-survival signaling. The research discovered that by either disrupting the ability of Calmodulin to sense calcium, or by starving tumor cells of calcium using a chelator, the most resistant of cell lines to Gemcitabine could be re-sensitized.

Researchers also discovered that this increased uptake of calcium was mediated by L-Type Channels, a major drug target in cardiovascular medicine. Millions of people use inhibitors of L-Type Calcium Channels (commonly referred to as a calcium channel blocker) to control their high blood pressure. “These medications are widely available, inexpensive, and safe”, Principe said. Using a high dose of the channel blocker Amlodipine reversed Gemcitabine resistance in vitro, as well as and in orthotopic xenograft models.

Amlodipine significantly extended the duration that genetically modified mouse models of advanced pancreatic cancer responded to Gemcitabine, increasing survival from an average of four to five months to as long as 13 months, Principe said.

Combined, the results suggest that the acquisition and maintenance of Gemcitabine resistance requires sustained calcium/Calmodulin signaling, which is mediated by L-Type Calcium Channels. For the first time, Rana’s lab showed that the addition of widely available, well-tolerated, low cost agents such as Amlodipine may improve drug responses in the clinical management of pancreatic cancer.

Daniel Principe working in lab

“Our whole team was delighted to have our work selected this year. This project is the result of an ongoing collaboration between Dr. Rana’s lab in the Department of Surgery, as well as investigators in the Department of Biochemistry and Molecular Genetics, the College of Pharmacy, and Northwestern University. Our lab would like to thank Dr. Elizaveta Benevolenskaya and her team in particular, as without them this work would not have been possible. I was also overjoyed to see Ben Gordon’s work recognized this year. Ben is one of my best friends in the MD/PhD program, and is really doing some amazing basic science research.”

Daniel Principe

Leave a Reply